Press releases

August 21, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

August 18, 2025

Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Read more

August 05, 2025

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

Read more

July 31, 2025

Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome

Read more

July 30, 2025

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

Read more

July 18, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

July 11, 2025

Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Read more

July 09, 2025

Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis

Read more

June 27, 2025

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

Read more

June 20, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more